Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma

Inclusion Criteria: 1. Age 18-75 years; 2. BCLC stage B HCC; 3. Received no previous anti-cancer treatment; 4. At least 1 measurable intrahepatic lesion based on the Response Evaluation Criteria in Solid Tumors criteria (RECIST) 1.1; 5. Adequate hematological, liver, renal function: 1. absolute neutrophil count ≥ 1.5×109/L; 2. platelet count ≥ 100×109/L; 3. hemoglobin concentration ≥ 90 g/L; 4. albumin ≥ 28 g/L; 5. total bilirubin \< 1.5 times the upper limit of normal; 6. alanine aminotransferase and aspartate aminotransferase \< 5 times the upper limit of normal; 7. blood urea nitrogen and serum creatinine concentration \< 1.5 times the upper limit of the normal range or less and creatinine clearance rate ≥ 45 mL/min; 6. Life expectancy of at least 3 months. Exclusion Criteria: 1. Acute or chronic active hepatitis B (HBV) or C (HCV) infection with HBV-DNA \> 2000 IU/ml or 104 copies/ml; hepatitis C virus RNA \> 103 copies/ml; HBsAg and anti-HCV antibody positive at the same time. Those who are below the above criteria after nucleoside based antiviral therapy may be enrolled; 2. Life-threatening bleeding event within the past 3 months, including the need for blood transfusion, surgical or local treatment, or continuous medication; 3. History of previous arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary artery embolism, deep vein thrombosis, or any other serious thromboembolism; 4. Use of aspirin (\>325 mg/day) or other drugs known to inhibit platelet function such as dipyridamole or clopidogrel for 10 consecutive days within 2 weeks prior to enrollment; 5. Uncontrolled hypertension, systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy; 6. Symptomatic congestive heart failure (New York Heart Association class II-IV); Symptomatic or poorly controlled arrhythmias; History of congenital long QT syndrome or corrected QT (QTc) \> 500 ms at screening; 7. Diagnosis of other malignant tumors within 5 years prior to enrollment; 8. Pregnant or lactating women or subjects planning to have a baby during the study period; 9. Accompanied with other uncontrolled co-morbidities; 10. Co-infection with HIV, known syphilis infection requiring treatment.